The U.S. Food and Drug Administration (FDA) has announced a new, albeit highly restricted, enforcement discretion policy for certain hemp-derived cannabidiol (CBD) products. This development occurs amidst a broader executive push to research medicinal access to cannabinoids, directly resulting in a narrow pathway for specific CBD products to be provided to Medicare patients without immediate FDA enforcement action.
Key Takeaways:
- General Risk Remains Low: For the broader industry, FDA enforcement risk remains low as long as products avoid therapeutic "disease" claims.
- Limited Scope: Enforcement discretion applies strictly to CBD provided to Medicare beneficiaries.
- Strict Criteria: Products must meet dietary supplement labeling standards, be uncontaminated, and not appeal to children.
- Executive Push: The policy follows a White House directive to improve medicinal access to hemp-derived cannabinoids.
A Narrow Window for Enforcement Discretion
On April 1, 2026, the FDA outlined its new stance on orally administered CBD products. However, industry experts warn that food and dietary supplement companies should not view this as a green light for widespread commercialization. The policy is explicitly tailored to a very specific use case.
To qualify for this limited enforcement discretion, a hemp-derived CBD product must meet four strict criteria:
- Dietary Supplement Framework: The product must be manufactured, marketed, and labeled consistently with dietary supplement rules, including a supplement facts panel and appropriate structure/function claims.
- Purity: The product must not be contaminated.
- Adult Focus: The product cannot be packaged, labeled, or marketed in a manner attractive to children.
- Medicare Provision: Crucially, the product must be provided to a beneficiary through a Medicare program (Title XVIII of the Social Security Act), directed by the patient's treating physician, and ancillary to covered medical services.
It is this fourth criterion that severely limits the policy's applicability for the general commercial market.
The Evolving Definition of Legal Hemp
This FDA action must be understood within the context of evolving federal definitions of hemp. Since the 2018 Farm Bill, "hemp" (Cannabis sativa L. with a delta-9 THC concentration of not more than 0.3% on a dry weight basis) has been excluded from the Controlled Substances Act's definition of marijuana.
However, the recently enacted Continuing Appropriations Act of 2026 further narrowed this definition. The law now explicitly excludes:
- Cannabinoids not capable of being naturally produced in the plant.
- Synthesized cannabinoids (even if they can be naturally produced).
- Cannabinoids that produce, or are marketed to produce, THC-like effects.
Executive Directives and Medicare Incentives
The FDA's decision was heavily influenced by recent actions from the Executive Office of the President. A directive was issued to the FDA, Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and the National Institutes of Health (NIH) to research ways to improve patient access to medicinal hemp-derived products.
Following this, CMS established a Substance Access Beneficiary Engagement Incentive (BEI). This program allows participating organizations to offer up to $500 per year in hemp products to eligible Medicare beneficiaries, providing the specific context for the FDA's new enforcement discretion.
Practical Advice for the Broader Industry
For CBD companies operating outside the Medicare framework, the immediate impact of this policy is negligible. However, legal experts advise that even if a product doesn't qualify for this specific enforcement discretion, adhering to the first three criteria (proper labeling, purity, and avoiding youth appeal) is a best practice to reduce overall liability and enforcement risk.
Practically speaking, the risk of FDA enforcement against general CBD-containing food or dietary supplements remains relatively low, provided companies strictly avoid making therapeutic or "disease-curing" claims on their labels or marketing materials.
